Ownership and insider activity for Vera Therapeutics, Inc. (VERA): recent transactions by executives and directors. Track how corporate insiders are trading the stock.
Vera Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of treatments for significant immunological disorders, primarily within the United States. Their leading therapeutic candidate is atacicept, a fusion protein that patients self-administer as a subcutaneous injection. This drug is currently undergoing Phase IIb clinical trials to treat immunoglobulin A nephropathy.
Price
| Price | $31.97 (closing price, November 4, 2026) |
| Market Cap | $2.3B |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-09-15 | Fordyce Marshall | M-Exempt | 18,500 | $54K |
| 2026-09-15 | Fordyce Marshall | M-Exempt | 18,500 | $54K |
| 2026-09-15 | Fordyce Marshall | S-Sale | 18,500 | $684K |
| 2026-09-11 | Young Joseph R | M-Exempt | 5,000 | $20K |
| 2026-09-11 | Young Joseph R | M-Exempt | 5,000 | $20K |
| 2026-09-02 | Fordyce Marshall | M-Exempt | 18,500 | $54K |
| 2026-09-02 | Fordyce Marshall | M-Exempt | 18,500 | $54K |
| 2026-09-02 | Fordyce Marshall | S-Sale | 18,500 | $650K |
| 2026-07-07 | Fordyce Marshall | M-Exempt | 46,250 | $134K |
| 2026-07-07 | Fordyce Marshall | M-Exempt | 46,250 | $134K |
Balance Sheet (10y)
| Year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $3.2M | $53.7M | $79.7M | $43.5M | $45.7M | $92.6M | $354.7M |
| Short-term Investments | 0 | 0 | 0 | $71.2M | $115.0M | $548.2M | $359.9M |
| Receivables | 0 | $52,000 | 0 | 0 | 0 | $3.8M | $3.3M |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $3.6M | $54.3M | $82.5M | $125.7M | $172.0M | $651.2M | $728.9M |
| Property, Plant & Equipment | $1.4M | 0 | 0 | $5.2M | $3.0M | $4.3M | $1.9M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $5.4M | $54.6M | $83.7M | $131.4M | $175.5M | $655.7M | $734.7M |
| Accounts Payable | $342,000 | $909,000 | $1.4M | $12.0M | $11.1M | $7.7M | $21.9M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $1.1M | $2.4M | $7.7M | $25.6M | $22.3M | $25.4M | $53.5M |
| Long-term Debt | 0 | 0 | $4.9M | $24.8M | $49.9M | $50.7M | $74.8M |
| Total Liabilities | $41.9M | $143.9M | $14.2M | $54.5M | $73.9M | $78.5M | $130.2M |
| Retained Earnings | -$38.0M | -$91.4M | -$124.1M | -$213.1M | -$309.1M | -$461.2M | -$760.9M |
| Total Equity | -$36.5M | -$89.3M | $69.6M | $76.9M | $101.7M | $577.2M | $604.5M |
| Total Debt | $132,000 | $2,000 | $4.9M | $31.3M | $53.7M | $54.6M | $77.3M |
| Net Debt | -$3.1M | -$53.7M | -$74.8M | -$83.4M | -$107.0M | -$586.2M | -$637.3M |
| Working Capital | $2.5M | $51.9M | $74.8M | $100.1M | $149.7M | $625.8M | $675.4M |
Financial Health
| Debt / Equity | 0.18 |
| Current Ratio | 10.92 |
| Piotroski F-Score | 1 |
| Altman Z-Score | 13.22 |
Profitability
| Return on Equity | -84.13% |
| Return on Invested Capital | -85.78% |
| Return on Assets | -75.40% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: DNTH · ARQT · BHVN · VRTX · 0QZU.L · MRNA · REGN · 0R2M.L
Explore sector: Healthcare · Biotechnology
More sections of VERA: Overview · Financials · Valuation · Estimates · Technical
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks